Biopump Maker Medgenics Lists on NYSE Amex

Executives and guests of Medgenics, Inc. (NYSE Amex: MDGN) visited the New York Stock Exchange (NYSE Amex) to celebrate the company’s April 8th, 2011 Listing. President, CEO, and Founder, Dr. Andrew Pearlman Ph.D. rang The Closing Bell.

About Medgenics:

Medgenics is developing and commercializing the Biopump, a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient's own skin biopsy for the treatment of a range of chronic diseases including anemia, hepatitis C and hemophilia. Medgenics believes this approach has multiple benefits compared with current treatments, which include regular and costly injections of therapeutic proteins.